The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing's Sarcoma, with a goal of preclinical evaluation leading to clinical testing.
The National Cancer Institute Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize antibody-based treatments of mesothelin-expressing cancers.
Researchers at the National Eye Institute have developed a new cytokine therapy that delivers functional interleukin 34 (IL-34) to the retina for treating ocular inflammatory diseases – such as uveitis and degenerative retinal diseases. Intraocular delivery of IL-34 protein or IL-34 gene expression system can effectively prevent retinal inflammation. Thus, it may be a promising strategy to produce long-lasting effects in suppressing abnormal retinal inflammation and preventing photoreceptor death.
Adoptive T Cell Therapy (ACT) has proven to effectively treat established tumors. This treatment consists of harvesting Tumor Infiltrated Lymphocytes (TIL) which specifically recognize cancer, expanding the tumor-specific TIL in vitro, and then reinfusing these cells into the patient for treatment. Both these lymphocytes and their T cell receptors (TCR) are valuable for cancer immunotherapy. Inventors from the National Cancer Institute (NCI) have developed an improved method to identify tumor-specific TCRs by reprogramming TIL into stem cells. This invention is available to license further development.
The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.
Researchers at the National Cancer Institute discovered small-molecule compounds containing 1-hydroxy-2-oxo-1,8-naphthyridine moieties whose activity against HIV-1 integrase mutants confer resistance to currently approved INSTIs. Preliminary rodent efficacy, metabolic, and pharmacokinetic studies have been completed by the NCI researchers. The National Cancer Institute seeks partners to commercialize this class of compounds through licensing or co-development.
Researchers at the National Cancer Institute (NCI) have developed peptidomimetic inhibitors that disrupt Polo-like kinase 1 (Plk1)-mediated protein interactions by targeting polo-box domain (PBD). The compounds are designed to selectively cause mitotic arrest in cancer cells with abnormal Plk1 expression. Researchers seek licensing and/or co-development research collaborations to further develop the inhibitors.
Adoptive cell therapy (ACT) using tumor-specific T cells leads to complete tumor regression in some cancer patients. However, limiting the efficacy of this therapy is that T cells become functionally exhausted and have short half-lives after adoptive transfer. Researchers at the National Cancer Institute (NCI) have discovered a novel method to generate long-lived memory tumor-specific T cells with enhanced tumor clearance and persistence upon in vivo transfer. NCI is seeking parties interested in licensing and/or co-developing potassium hydroxy citrate to promote longevity and efficacy of tumor-specific T cells.
The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
Researchers at the National Cancer Institute (NCI) have isolated T cell receptors (TCRs) that target specific mutations in the epidermal growth factor receptor (EGFR). The mutated protein recognized by these TCRs is frequently expressed in non-small cell lung cancer (NSCLC). These TCRs can be used for a variety of therapeutic applications, including engineered adoptive cell immunotherapy. Researchers at the NCI seek licensing and/or co-development research collaborations for these novel T cell receptors that recognize EGFR mutations.
Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis. The National Institute on Aging's Immunotherapeutics Unit, is seeking parties interested in licensing or co-development of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape.
Researchers at the National Cancer Institute (NCI) have developed single domain human CD4 proteins to inhibit HIV-1 entry and improved human domain antibodies against HIV-1. Fusion proteins comprising the single domain CD4 and HIV-1 antibody can be used to effectively neutralize HIV-1 in vitro. Researchers seek licensing for development of these antibody-based therapeutics for the treatment of HIV-1.
Researchers at the National Cancer Institute (NCI) have isolated seven monoclonal antibodies that bind to the human epidermal growth factor receptor variant III (EGFRvIII) but not wildtype EGFR. The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Antibodies that specifically recognize and bind to the unshed portion (“stalk”) of human mesothelin are strong therapeutic candidates because they maintain contact with the cancer cell for a longer duration than other anti-mesothelin antibodies that are currently available. The National Cancer Institute (NCI) has developed such antibodies that specifically recognize and bind to the stalk of human mesothelin with high affinity. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
Researchers at the National Cancer Institute (NCI) have developed a method to epigenetically reprogram CD8+ T cell fate by expressing elevated levels of the polycomb-like protein, Phf19. This technology is useful for improving T cell-based immunotherapies (such as CAR therapies) to treat a range of infectious diseases and cancers. NCI seeks licensing or co-development partners for this invention.
The National Eye Institute's Ophthalmic Genetics and Visual Function Branch seeks interested parties to co-develop the use of nitisinone (NTBC) for oculocutaneous albinism or as a treatment for increasing pigmentation in the eyes, hair and/or skin of patients.
Researchers at the National Cancer Institute (NCI) have developed small molecule compounds that inhibit activity of hypoxia inducible factor 1 (HIF-1). The HIF-1 inhibitor compounds are designed around the scaffold of naturally occurring metabolite eudistidine. The invention compounds have demonstrated activity against cancer and malaria in vitro.
Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process; the biodegradable microbead or microparticle is useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest. The microparticles have a matrix structure comprised of the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component (e.g. gelatin, chondroitin sulfate, avidin).
Researchers at the National Eye Institute (NEI) have developed a novel therapeutic strategy of using recombinant IL-24 protein to treat inflammatory diseases that involve the proinflammatory T-helper 17 cell (Th17) response, such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. Researchers at the NEI seek licensing and/or co-development research collaborations for co-developing this technology as strategic partners or licensing it for commercialization.